Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan;33(1):79-86.
doi: 10.1007/s11606-017-4205-9. Epub 2017 Oct 31.

Diabetes Screening among Antipsychotic-Treated Adults with Severe Mental Illness in an Integrated Delivery System: A Retrospective Cohort Study

Christina Mangurian  1   2 , Dean Schillinger  3   4 , John W Newcomer  5 , Eric Vittinghoff  6 , Susan Essock  7 , Zheng Zhu  8 , Wendy Dyer  8 , Julie Schmittdiel  8
Affiliations

Diabetes Screening among Antipsychotic-Treated Adults with Severe Mental Illness in an Integrated Delivery System: A Retrospective Cohort Study

Christina Mangurian et al. J Gen Intern Med. 2018 Jan.

Abstract

Background: Severe mental illness (SMI) is associated with increased risk for type 2 diabetes, partly due to adverse metabolic effects of antipsychotic medications. In public health care settings, annual screening rates are 30%. We measured adherence to national diabetes screening guidelines for patients taking antipsychotic medications.

Objective: To estimate diabetes screening prevalence among patients with SMI within an integrated health care system, and to assess characteristics associated with lack of screening.

Design: Retrospective cohort study.

Participants: Antipsychotic-treated adults with SMI. We excluded participants with known diabetes.

Main measures: Primary outcome was screening via fasting glucose test or hemoglobin A1c during a 1-year period.

Key results: In 2014, 16,754 patients with SMI diagnoses were receiving antipsychotics. Seventy-four percent of these patients' providers ordered diabetes screening tests that year, but only 55% (9247/16,754) received screening. When the observation time frame was extended to 2 years, 73% (12,250/16,754) were screened. Adjusting for sex and race/ethnicity, young adults (aged 18-29 years) were less likely to receive screening than older age groups [adjusted RR (aRR) 1.23-1.57, p < 0.0001]. Compared to whites, screening was more common for Asians (aRR 1.141, 95% CI 1.089-1.195, p < 0.0001), less common for blacks (aRR 0.946, 95% CI 0.898-0.997, p < 0.0375), and no different for Hispanics (aRR 1.030, 95% CI 0.988-1.074, p = 0.165). Smokers were less likely to be screened than non-smokers (aRR 0.93, 95% CI 0.89-0.97, p < 0.0008). Utilization of either mental health or primary care services increased the likelihood of screening.

Conclusions: While almost three-fourths of adults with SMI taking antipsychotic medications received a lab order for diabetes screening, only 55% received screening within a 12-month period. Young adults and smokers were less likely to be screened, despite their disproportionate metabolic risk. Future studies should assess the barriers and facilitators with regard to diabetes screening in this vulnerable population at the patient, provider, and system levels.

Keywords: diabetes screening; quality of care; severe mental illness.

PubMed Disclaimer

Conflict of interest statement

JN receives consulting fees from Sunovion Pharmaceuticals, and serves on a data safety monitoring board for Amgen outside the submitted work. All other authors have no potential conflicts of interest.

References

    1. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prevent Chronic Dis. 2006;3(2):A42. - PMC - PubMed
    1. Osborn DP, Wright CA, Levy G, King MB, Deo R, Nazareth I. Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis. BMC Psychiatry. 2008;8:84. doi: 10.1186/1471-244x-8-84. - DOI - PMC - PubMed
    1. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1–93. - PubMed
    1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care; 2004. p. 596-601. - PubMed
    1. Essock SM, Covell NH, Leckman-Westin E, Lieberman JA, Sederer LI, Kealey E, et al. Identifying clinically questionable psychotropic prescribing practices for Medicaid recipients in New York state. Psychiatr Serv. 2009;60(12):1595–602. doi: 10.1176/appi.ps.60.12.1595. - DOI - PubMed

Publication types

MeSH terms

Substances